These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1148 related articles for article (PubMed ID: 19514381)
1. [HLA-E molecule induction on the surface of tumor cells protects them from cytotoxic lymphocytes]. Berezhnoĭ AE; Chernisheva AD; Zakeeva IR; Danilova AB; Danilov AO; Moiseenko VM; Geraghty D; Gnuchev NV; Georgiev GP; Kibardin AV; Larin SS Vopr Onkol; 2009; 55(2):224-9. PubMed ID: 19514381 [TBL] [Abstract][Full Text] [Related]
2. HLA-G expression in malignant melanoma. Rebmann V; Wagner S; Grosse-Wilde H Semin Cancer Biol; 2007 Dec; 17(6):422-9. PubMed ID: 17689098 [TBL] [Abstract][Full Text] [Related]
3. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. Rodríguez T; Méndez R; Del Campo A; Jiménez P; Aptsiauri N; Garrido F; Ruiz-Cabello F BMC Cancer; 2007 Feb; 7():34. PubMed ID: 17319941 [TBL] [Abstract][Full Text] [Related]
4. [HLA-G: a tolerance molecule implicated in the escape of tumors from immunosurveillance]. Paul P; Rouas-Freiss N; Carosella ED Pathol Biol (Paris); 1999 Oct; 47(8):766-70. PubMed ID: 10573693 [TBL] [Abstract][Full Text] [Related]
5. The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells. Giorda E; Sibilio L; Martayan A; Moretti S; Venturo I; Mottolese M; Ferrara GB; Cappellacci S; Eibenschutz L; Catricalà C; Grammatico P; Giacomini P Cancer Res; 2003 Jul; 63(14):4119-27. PubMed ID: 12874016 [TBL] [Abstract][Full Text] [Related]
6. Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5. Sensi M; Pietra G; Molla A; Nicolini G; Vegetti C; Bersani I; Millo E; Weiss E; Moretta L; Mingari MC; Anichini A Int Immunol; 2009 Mar; 21(3):257-68. PubMed ID: 19181932 [TBL] [Abstract][Full Text] [Related]
7. Rapid expansion of tumor-reactive cells from HLA-matched siblings for adoptive immunotherapy of melanoma. Gottlieb DJ; Micklethwaite K; Bradstock KF; Li YC Cytotherapy; 2007; 9(2):133-43. PubMed ID: 17453965 [TBL] [Abstract][Full Text] [Related]
8. Expression and regulation of non-classical HLA-G in renal cell carcinoma. Dunker K; Schlaf G; Bukur J; Altermann WW; Handke D; Seliger B Tissue Antigens; 2008 Aug; 72(2):137-48. PubMed ID: 18721274 [TBL] [Abstract][Full Text] [Related]
9. Ionizing radiation modulates the surface expression of human leukocyte antigen-G in a human melanoma cell line. Michelin S; Gallegos CE; Dubner D; Favier B; Carosella ED Hum Immunol; 2009 Dec; 70(12):1010-5. PubMed ID: 19665041 [TBL] [Abstract][Full Text] [Related]
10. Expression of the non-classical HLA-G antigen in tumor cell lines is extremely restricted. Poláková K; Russ G Neoplasma; 2000; 47(6):342-8. PubMed ID: 11263857 [TBL] [Abstract][Full Text] [Related]
11. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. Komohara Y; Harada M; Ishihara Y; Suekane S; Noguchi M; Yamada A; Matsuoka K; Itoh K Oncol Rep; 2007 Dec; 18(6):1463-8. PubMed ID: 17982631 [TBL] [Abstract][Full Text] [Related]
12. Regulatory effect of interferon-gamma and phorbol esters on the surface expression and biosynthesis of MHC class I antigens by human leukemia cells. Guha A; Dainiak N; Freedman M; Goldschneider I; Cone RE Cell Immunol; 1993 Oct; 151(2):404-13. PubMed ID: 8402945 [TBL] [Abstract][Full Text] [Related]
13. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis. Riemersma SA; Oudejans JJ; Vonk MJ; Dreef EJ; Prins FA; Jansen PM; Vermeer MH; Blok P; Kibbelaar RE; Muris JJ; Schuuring EM; Kluin PM J Pathol; 2005 Jul; 206(3):328-36. PubMed ID: 15887291 [TBL] [Abstract][Full Text] [Related]
14. Effector T cell analysis of melanoma tumor-infiltrating lymphocyte cultures using HLA-ABC semimatched melanoma cell lines. Carlsson B; Sadeghi A; Bengtsson M; Wagenius G; Tötterman TH J Immunother; 2008 Sep; 31(7):633-43. PubMed ID: 18600181 [TBL] [Abstract][Full Text] [Related]
15. Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2'-deoxycytidine. Yan WH; Lin AF; Chang CC; Ferrone S Cell Res; 2005 Jul; 15(7):523-31. PubMed ID: 16045815 [TBL] [Abstract][Full Text] [Related]
16. Structure, expression and function of HLA-G in renal cell carcinoma. Seliger B; Schlaf G Semin Cancer Biol; 2007 Dec; 17(6):444-50. PubMed ID: 17707652 [TBL] [Abstract][Full Text] [Related]
18. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Rouas-Freiss N; Moreau P; Ferrone S; Carosella ED Cancer Res; 2005 Nov; 65(22):10139-44. PubMed ID: 16287995 [TBL] [Abstract][Full Text] [Related]
19. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity. Riquelme E; Carreño LJ; González PA; Kalergis AM Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198 [TBL] [Abstract][Full Text] [Related]